The FDA has granted Parascript approval for its AccuDetect software, designed to aid in early breast cancer diagnosis. In an analysis, the technology helped improve the detection of tumors missed in initial exams by 18.8% and achieved a 14.2% reduction in the number of follow-up tests from false positives, the company said.

Related Summaries